跳到正文
原文
Nature 健康护理主题·· 8 小时前精选AI 评分70

系统性红斑狼疮患者心血管风险因素及预防策略:一项综述

Social determinants of health, lifestyle factors, and artificial intelligence in cardiovascular risk stratification for systemic lupus erythematosus: a narrative review

AI 导读

文章综述了系统性红斑狼疮患者的心血管风险因素,包括社会经济因素、生活方式和人工智能在风险预测中的应用。研究指出,这些因素共同作用增加了心血管疾病的风险,强调了综合预防策略的重要性。

推荐理由

文章综合分析了系统性红斑狼疮患者的心血管风险因素及预防策略,为临床实践提供了重要参考。

正文 · 原文

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement and alternating periods of disease flares and remission. While SLE affects multiple organ systems, including the skin, joints, kidneys, and nervous system, cardiovascular disease (CVD) has emerged as the leading cause of morbidity and mortality in this patient population1,2,3,4. Patients with SLE face a two- to three-fold increased risk of developing CVD compared with age-matched controls5, 6. This elevated cardiovascular risk stems from both the chronic systemic inflammation inherent to SLE and the combination of traditional cardiovascular risk factors, including hypertension, dyslipidemia, and diabetes mellitus7,8,9,10. Lupus nephritis (LN), a serious kidney complication of SLE caused by immune-mediated inflammation and damage to the kidneys, affects up to 60% of patients with SLE over time, further complicating cardiovascular risk through its association with hypertension, proteinuria, and metabolic derangements5. Lifestyle factors represent another critical domain influencing CVD risk in SLE. Physical inactivity, tobacco use, poor dietary patterns, and excessive alcohol consumption can exacerbate systemic inflammation and may contribute to accelerated atherosclerotic plaque formation11,12,13,14.

Emerging artificial intelligence (AI) and machine learning (ML) approaches can integrate genomic, clinical, and socioenvironmental data into risk models tailored to diverse SLE populations, offering a promising avenue for equity-centered CVD prevention. This narrative review synthesizes current evidence on the socioeconomic and lifestyle determinants of CVD in SLE, examines health disparities affecting vulnerable populations, and explores AI’s emerging role in advancing precision cardiovascular care for patients with SLE. To our knowledge, prior reviews have addressed individual domains, including CVD risk factors in SLE3, 8, 9, social determinants of health (SDOH) and health disparities in SLE15, 16 and AI/ML applications in SLE, including emerging approaches to CVD risk prediction17, but have not integrated these domains within a unified, equity-centered framework. By bringing these areas together, this review addresses an important gap in the literature and translates this evidence into clinically actionable, equity-centered guidance for practitioners managing patients with SLE.

Methods

Literature search strategy

We conducted a comprehensive search of peer-reviewed literature across four electronic databases: PubMed/MEDLINE, CINAHL, Scopus, and Web of Science. We restricted the search to publications from January 2012 to March 2026 to capture contemporary evidence on CVD risk in SLE and include landmark studies. We included earlier seminal papers when they provided foundational evidence. We limited the search to English-language publications.

Search terms

We developed search queries for four thematic domains using Medical Subject Headings (MeSH) and free-text terms. Domain 1 (SLE and CVD): (“systemic lupus erythematosus” OR “SLE”) AND (“cardiovascular disease” OR “CVD” OR “atherosclerosis”). Domain 2 (SDOH and health disparities): (“social determinants of health” OR “socioeconomic status” OR “health disparities” OR “structural racism”). Domain 3 (lifestyle): (“physical activity” OR “exercise” OR “tobacco” OR “dietary patterns” OR “obesity”). Domain 4 (AI/ML): (“artificial intelligence” OR “machine learning” OR “predictive model” OR “risk stratification”). We combined domain terms with Boolean operators as appropriate.

Inclusion and exclusion criteria

Studies were included if they met the following criteria: (1) enrolled adult patients with SLE (≥ 18 years); (2) reported cardiovascular outcomes, CVD risk factors, or CVD risk prediction; (3) addressed at least one of the following thematic domains—SDOH, lifestyle factors, or AI/ML-based CVD risk prediction; and (4) were published as original research articles, systematic reviews, meta-analyses, or clinical practice guidelines in peer-reviewed journals. We excluded studies focused exclusively on pediatric SLE, those that did not report cardiovascular-relevant outcomes, and conference abstracts, editorials, or letters lacking original data. The database search yielded approximately 1,840 records. After removing duplicates (~ 310) and screening titles and abstracts, we reviewed 120 studies in full text. A final set of 39 contemporary studies met all inclusion criteria and were incorporated into the narrative synthesis. In addition, we included two seminal pre-2012 publications identified through reference tracking when they provided foundational evidence.

Evidence synthesis and quality assessment

This review was conducted and reported in accordance with the SANRA (Scale for the Assessment of Narrative Review Articles) framework for narrative review quality18 Evidence quality ratings in Table 1 (High, Moderate, or Low) reflect the volume, consistency, and methodological rigor of supporting evidence: High = SLE-specific RCTs or meta-analyses; Moderate = observational/cohort data; Low = expert consensus or extrapolation. We synthesized evidence narratively, critically appraising study designs, populations, outcome measures, and the strength and consistency of findings. Studies from diverse geographic regions and multiethnic cohorts, including GLADEL and LUMINA, were specifically sought to ensure equitable representation of the populations most affected by CVD disparities in SLE19, 20.

Table 1 Cardiovascular disease risk factors in systemic lupus erythematosus and evidence-based healthcare provider interventions

Full size table

Social determinants of health and CVD risk in SLE

Socioeconomic status and healthcare access

Socioeconomic factors are associated with CVD risk in SLE. Lower income, limited educational attainment, and food insecurity create barriers to prevention and disease management15, 27, 31. Health-care affordability remains a challenge and may reduce adherence and access to specialist care. Individuals with SLE from lower socioeconomic backgrounds have higher rates of cardiovascular risk factors and adverse outcomes than those with higher socioeconomic status24. In the Hopkins cohort analyzed by Maynard et al., several income-related associations differed by ethnicity and were not uniformly independent of disease activity or treatment24.

Healthcare access extends beyond insurance coverage to include specialty care, language-concordant providers, culturally competent teams, and flexible scheduling32. Communication barriers are not solely a function of patient education or health literacy. They also reflect the care team’s responsibility to use plain language, avoid unnecessary jargon, and explain diagnosis, treatment, and long-term management in culturally responsive terms25. This requires coordinated efforts not only from physicians but also from nurses, educators, interpreters, and patient navigators, who can use plain language, visual aids, and teach-back methods to support patient understanding and empower individuals with SLE to actively participate in managing their cardiovascular health25.

Racial and ethnic disparities

Individuals from historically racial and ethnic minority groups, specifically Black (per AMA/NIH style conventions) and Hispanic populations, experience a disproportionately high burden of SLE and associated cardiovascular complications. SLE prevalence is approximately three times higher in individuals of African descent relative to White individuals. Individuals of African descent with SLE have a 14% higher risk of developing CVD3, 23. Hispanic patients with SLE similarly face increased disease severity and cardiovascular complications. Further studies have shown that individuals of African and Asian descent may experience more severe disease manifestations than White individuals16, 23.

Studies have also shown differential treatment patterns; individuals of African and Hispanic descent receive less intensive disease-modifying therapies, fewer specialist referrals, and less aggressive CVD risk factor management when compared with patients of European descent with similar disease severity16, 20, 32, 33

Globally, SLE-associated CVD disproportionately affects populations in Latin America and the Global South, where socioeconomic disadvantages, limited healthcare infrastructure, and ethnic heterogeneity co-occur. The GLADEL (Grupo Latinoamericano de Estudio del Lupus) multinational cohort of more than 1,200 patients with SLE from Latin American countries documented ethnic and socioeconomic heterogeneity in disease expression, organ damage, and outcomes, with Mestizo (individuals of mixed Indigenous American and European ancestry) and Afro-Latin patients experiencing more severe disease trajectories than White patients19. The LUMINA (Lupus in Minorities: Nature versus Nurture) multiethnic US cohort demonstrated that poverty, low educational attainment, and social disadvantage independently predicted higher disease activity over time in Hispanic, Black, and White patients with SLE20. Socioeconomic disadvantage in LUMINA is therefore best interpreted as a driver of more severe SLE, which may later contribute to cardiovascular risk, rather than as direct evidence of CVD events. Evidence linking socioeconomic disadvantage to cardiovascular events and risk in SLE comes from other cohorts3, 15, 23. Together, these studies support prevention strategies that address structural and social determinants across diverse population contexts.

Lifestyle factors and CVD risk in SLE

Physical activity and exercise

Physical inactivity is highly prevalent among patients with SLE, due to disease-related fatigue, arthralgia, fear of triggering flares, and psychosocial factors including depression and anxiety11, 13. However, regular physical activity confers substantial cardiovascular benefits, including improvements in endothelial function, lipid profiles, insulin sensitivity, blood pressure control, and inflammatory markers11, 13.

A systematic review and meta-analysis by Lu et al. demonstrated that exercise interventions in SLE led to significant improvements in aerobic capacity, muscle strength, fatigue, and health-related quality of life without increasing disease activity or adverse events11. Both aerobic exercise and resistance training appear safe and beneficial for most patients when appropriately prescribed and monitored. International consensus guidelines now endorse individualized exercise prescriptions for people with SLE13. Healthcare providers should assess physical activity levels at every clinical encounter and consider referral to physical therapy for supervised programming when indicated.

Tobacco use

Cigarette smoking is one of the most potent modifiable CVD risk factors in SLE, yet smoking rates among patients with SLE often exceed those in the general population14, 21 Tobacco use is associated with increased disease activity, more frequent flares, accelerated atherosclerosis, elevated cardiovascular event risk, and reduced immunosuppressive medication efficacy14, 21.

Raymond et al. reported that smoking in SLE was associated with elevated B-cell activating factor (BAFF) levels and decreased interferon-gamma levels, key immunological perturbations in SLE pathogenesis21 Evidence-based cessation approaches, including behavioral counseling, nicotine replacement therapy, and pharmacotherapy (varenicline, bupropion), should be prioritized as a fundamental component of CVD prevention for all patients who use tobacco.

Dietary patterns

Dietary patterns substantially influence cardiovascular risk in SLE by affecting lipid metabolism, glucose homeostasis, body weight, blood pressure, and systemic inflammation.12, 34 The Mediterranean dietary pattern, characterized by high consumption of fruits, vegetables, whole grains, legumes, nuts, olive oil, and fish, has been widely studied for cardiovascular benefit in the general population and is emerging as a promising dietary approach in SLE. Pocovi-Gerardino et al. reported that higher adherence to the Mediterranean diet was associated with lower disease activity, improved lipid profiles, reduced inflammatory markers, and lower cardiovascular risk scores in patients with SLE34. Dietary counseling should emphasize anti-inflammatory food choices, adequate omega-3 fatty acid intake, sodium restriction, and strategies to maintain a healthy body weight. Referral to registered dietitians with autoimmune disease expertise is recommended.

Obesity and body weight

Obesity is increasingly prevalent among patients with SLE and contributes to CVD risk through insulin resistance, dyslipidemia, hypertension, pro-inflammatory adipokine production, and mechanical cardiovascular stress22. Corticosteroid therapy promotes weight gain and central fat accumulation, further compounding metabolic risk. Comprehensive weight management, combining dietary modification, structured exercise, and behavioral strategies, has demonstrated efficacy for weight loss and CVD risk reduction in SLE22. It should be delivered without stigma, acknowledging the complex biological, psychological, and social factors that influence body weight.

Integrating social and lifestyle determinants: holistic framework

CVD in patients with SLE cannot be understood through a reductionist lens. A socioecological framework recognizes that cardiovascular health emerges from the dynamic interplay of biological vulnerability, health behaviors, social circumstances, healthcare system factors, and broader structural determinants27. Educational attainment influences health literacy and self-management capacity. Socioeconomic resources determine access to nutritious foods, safe environments for physical activity, and quality healthcare. Racial and ethnic identity shapes lifetime exposure to discrimination, residential segregation, environmental hazards, and differential treatment within healthcare systems, creating compounding disadvantages for the most vulnerable populations. Incorporating these social and lifestyle determinants into cardiovascular risk prediction models may improve risk stratification beyond traditional clinical variables.

Shantz et al.‘s biopsychosocial synthesis similarly argues for moving beyond isolated biomedical risk factors27. Fig. 1 summarizes an integrated framework in which AI is a potential analytic layer—not a substitute for clinical judgment or structural intervention. Clinicians may use validated social needs tools, including the Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences (PRAPARE) and the Accountable Health Communities Health-Related Social Needs Screening Tool. Screening should occur only when referral pathways, privacy safeguards, and patient preferences are addressed; evidence that screening alone improves SLE-CVD outcomes is insufficient.

Fig. 1

Conceptual framework: multilevel determinants of cardiovascular risk in systemic lupus erythematosus (SLE). Upstream determinants → lifestyle and care → cardiovascular outcomes | AI supports analysis and care; it is not a causal determinant. Abbreviations: SLE, systemic lupus erythematosus; AI, artificial intelligence; CVD, cardiovascular disease. * AI tools in the analytic layer are redeployed research tools. Improved model discrimination (e.g., higher area under the receiver operating characteristic curve [AUC]) is necessary but not sufficient for clinical utility. Improved patient outcomes require prospective validation; such evidence is not yet available for the SLE-specific models reviewed. Note. Arrows represent conceptual pathways through which upstream determinants may contribute to cardiovascular outcomes, directly or through lifestyle and care mediators. For observational evidence, directional arrows indicate hypothesized associations rather than established causal relationships

SLE disease-specific factors interact with social determinants to compound CVD risk through biologically mediated pathways. High disease activity (SLEDAI), cumulative organ damage (SLICC Damage Index), lupus nephritis (affecting approximately 40–60% of patients across diverse SLE cohorts), prolonged corticosteroid exposure, and autoantibody profiles (anti-dsDNA, anti-phospholipid antibodies, low complement) each independently elevate CVD risk5, 31. Crucially, patients with lower socioeconomic status may experience delays in diagnosis, less intensive immunosuppressive management, and higher rates of lupus nephritis-related organ damage, creating a biologically mediated pathway through which structural disadvantage may amplify disease severity and cardiovascular risk15, 24, 32.

Consistent with this integrated perspective, Shantz et al. used a scoping review methodology to map the biopsychosocial determinants of CVD in SLE, identify research gaps, and emphasize the need to move beyond traditional biomedical models toward approaches that explicitly address social determinants, psychological factors, and structural barriers to cardiovascular health equity27. Routine screening for SDOH using validated tools such as the Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences (PRAPARE) or the Accountable Health Communities Health-Related Social Needs Screening Tool should be integrated into SLE clinical care. Identify social needs and pair them with robust referral systems that connect patients to community resources, social services, community health workers, patient navigators, and social workers. Partnerships with food banks, housing assistance programs, and transportation services can help reduce barriers to optimal CVD prevention and management.

Clinical implications and recommendations

The recommendations that follow are differentiated by evidence source and strength. Recommendations supported by SLE-specific trial or cohort evidence are rated High/SLE-specific. Those drawn from general cardiovascular guidelines (ACC/AHA, EULAR) extrapolated to SLE are rated Moderate or Low/Extrapolated; these require clinical judgment pending SLE-specific trial data, as noted in Table 1.

Healthcare providers play a pivotal role in mitigating CVD risk among patients with SLE through comprehensive risk assessment, evidence-based interventions, patient education, and advocacy for health equity. Table 1 summarizes key CVD risk factors in SLE and corresponding evidence-based healthcare provider interventions. The following clinical recommendations synthesize evidence from the reviewed literature:

  • Systematically screen for unmet social needs and connect patients with appropriate resources. Collaborate with social workers, community health workers, and community-based organizations to address food insecurity, housing instability, transportation challenges, and financial constraints. Advocate for policies expanding access to affordable healthcare, healthy foods, and safe neighborhoods27, 33.

  • Aggressive management of traditional risk factors: Patients with SLE require more intensive CVD risk factor targets than those recommended for the general population.16 Appropriate targets include blood pressure <130/80 mm Hg, LDL-cholesterol <70 mg/dL in high-risk individuals, and HbA1c <7% in those with diabetes. Statin therapy should be initiated based on individualized cardiovascular risk assessment using the ACC/AHA Pooled Cohort Equations (≥10-year ASCVD risk ≥7.5%) or EULAR recommendations, recognizing that SLE independently amplifies risk beyond what standard calculators capture; statin therapy may be appropriate at a lower calculated risk threshold in patients with active disease, lupus nephritis, or other SLE-specific risk-modifying factors35.

  • Promotion of healthy lifestyle behaviors: Structured programs addressing physical activity, dietary patterns, weight management, and smoking cessation should be core components of SLE care. Individualized exercise routines based on disease activity and functional capacity. Dietary counseling should emphasize Mediterranean-style eating patterns, sodium restriction, and adequate micronutrient intake.

  • Medication optimization: Minimize cumulative corticosteroid exposure by initiating steroid-sparing immunosuppressive agents early. Continue hydroxychloroquine unless contraindicated, given its favorable effects on lipid profiles and thrombosis risk. Consider cardioprotective medications (ACE inhibitors or ARBs, statins, low-dose aspirin in appropriate candidates) based on individual risk profiles28, 30

  • Health literacy enhancement: Provide patient education using plain language, visual aids, and teach-back methods to ensure comprehension. Culturally tailored educational materials enhance relevance and engagement. Shared decision-making approaches that honor patient preferences and values strengthen therapeutic alliances and improve adherence25, 28.

  • Address social determinants: Systematically screen for unmet social needs and connect patients with appropriate resources. Collaborate with social workers, community health workers, and community-based organizations to address food insecurity, housing instability, transportation challenges, and financial constraints. Advocate for policies expanding access to affordable healthcare, healthy foods, and safe neighborhoods27, 33.

  • Culturally responsive care: Recognize and address the impact of structural racism and discrimination on health outcomes. Ensure access to professional interpretation services, translation of medical information into the patient’s preferred language, and, where possible, culturally concordant providers. Build trust through consistent, respectful, non-judgmental interactions.

Most of the evidence reviewed comes from high-income countries, particularly the United States. In low- and middle-income countries (LMICs), where SLE prevalence is high and disease expression is often more severe due to delayed diagnosis and limited treatment access, implementation challenges are greater. Barriers include limited availability of rheumatology specialists, restricted access to immunosuppressive therapies, fragmented or absent health insurance systems24. and inadequate informatics infrastructure for AI deployment. GLADEL cohort data from Latin America underscore that those social determinants in LMIC contexts compound CVD risk through pathways distinct from those documented in North American cohorts19. Future research and clinical guideline development must explicitly address these global realities to ensure advances in SLE-CVD prevention benefit all affected populations equitably.

Artificial intelligence and precision medicine in SLE-CVD risk prediction

The promise of machine learning for CVD risk stratification

While AI and machine-learning approaches show promise for CVD risk stratification in SLE, the current evidence base remains preliminary. The SLE-specific models reviewed (SLECRISK and the gradient boosting model) were developed in single-center academic cohorts and, to our knowledge, have not undergone prospective external validation in an independent SLE population36, 37. These tools are not ready for widespread clinical use.

In general-population cohorts, including the Multi-Ethnic Study of Atherosclerosis (MESA), machine-learning models have outperformed conventional equations such as the ACC/AHA Pooled Cohort Equations38, 39. Those findings demonstrate feasibility; they are not a substitute for SLE-specific validation. Improved discrimination (for example, a higher AUC) is necessary but not sufficient for clinical utility. Whether AI-guided risk stratification improves patient outcomes requires prospective evaluation, which is not yet available for the SLE-specific models reviewed36, 37.

Earlier work in the Multi-Ethnic Study of Atherosclerosis (MESA) demonstrated that ML models outperformed the ACC/AHA risk calculator for cardiovascular risk prediction. Importantly, improved discriminative performance (e.g., higher area under the curve [AUC] values) is a necessary but not sufficient condition for clinical utility39. Whether AI-guided cardiovascular risk stratification translates into improved patient outcomes or changes in clinical practice requires prospective evaluation evidence that does not yet exist for any of the SLE-specific models reviewed17, 36, 37, 39 establishing the foundation for SLE-specific AI approaches. This synthesis examines the evidence with these caveats in view.

Recent advances in SLE-specific CVD risk prediction

Recent advances in SLE-specific cardiovascular risk prediction have accelerated the development of machine learning models tailored to the unique clinical and immunologic features of systemic lupus erythematosus. Choi et al. introduced SLECRISK, a novel ML-based tool trained on longitudinal data from 1,243 patients with SLE followed for 10 year36. The model integrates traditional CVD risk factors with SLE-specific variables including disease activity, disease duration, serum creatinine, and autoantibody profiles (anti-dsDNA, anti-RNP, lupus anticoagulant, and anti-Ro), as well as complement levels. SLECRISK achieved a sensitivity of 0.74 for identifying patients at moderate-to-high CVD risk (≥ 7.5%), outperforming the ACC/AHA Pooled Cohort Equations (sensitivity 0.38). Notably, it identified 3.4-fold higher-risk patients, particularly younger women with severe SLE who lacked traditional CVD risk factors but exhibited significant disease-related vulnerability.

Building on this progress, Liu et al. developed an interpretable gradient boosting machine (GBM) model to predict early cardiovascular involvement in SLE37. Using data from 1,023 patients with a median follow-up exceeding 10 years, the model identified arthritis, hypertension, HDL-cholesterol, LDL-cholesterol, C-reactive protein, erythrocyte sedimentation rate, and total cholesterol as influential predictors. By incorporating the DALEX interpretability framework, the authors visualized individualized risk profiles and each variable’s relative contribution, addressing the common “black box” critique of machine-learning approaches.

Liu C et al. used weighted gene coexpression network analysis with LASSO, SVM-RFE, and random forest to identify five hub genes (SPI1, MMP9, C1QA, CX3CR1, and MNDA) associated with atherosclerosis risk in SLE. They reported nomogram AUCs of 0.900–0.981 in public transcriptomic datasets17. That result applies to gene-based atherosclerosis risk prediction; it does not establish a pooled AUC across clinical events, arrhythmias, or heart failure.

The two SLE-specific models (SLECRISK and the GBM model) have important limitations. Both were developed and internally validated in single-center academic cohorts (1,243 and 1,023 patients, respectively) and, to our knowledge, have not undergone prospective external validation in an independent, diverse SLE population36, 37. Sample sizes are modest relative to feature complexity, which increases the risk of overfitting, and training cohorts may not represent community, safety-net, or LMIC populations. Researchers should acknowledge these constraints before clinical deployment.

A promising research direction is integration of social determinants of health into CVD prediction models. Electronic health records increasingly capture structured data on insurance, education, neighborhood deprivation, housing, and food security, and natural language processing can recover related information from clinical notes. Models that combine biological, clinical, and social data may improve risk stratification and help identify patients who need social support as well as medical management. ²⁵ This approach remains conceptual until such models are developed and externally validated in SLE.

At the same time, natural language processing can extract additional information from unstructured clinical notes, including documentation of housing instability, food insecurity, or transportation barriers. Models that combine biological, clinical, and SDOH data may improve predictive performance while helping identify patients who could benefit from targeted social support interventions alongside medical management27. This integrative approach supports a more holistic strategy that triggers both clinical action and SDOH-informed care pathways, with the potential to improve cardiovascular risk management in SLE.

Implementation challenges and ethical considerations

Algorithmic bias and health equity

ML models can perpetuate or amplify existing health disparities if training datasets underrepresent minority populations, exclude relevant SDOH variables, or encode biased clinical decisions.36, 39 Rigorous attention to training-data representativeness, transparent reporting of model performance across demographic subgroups, and continuous monitoring for disparate impact are essential.36, 39 In addition, inclusive model development practices, such as involving frontline clinicians, patients, and community stakeholders who understand the lived realities and care contexts of the populations represented in the data, can help ensure that annotation, validation, and interpretation processes do not inadvertently reinforce structural inequities. Although empirical work in SLE-specific AI is still emerging, these principles are increasingly recognized as foundational to the equitable implementation of ML-based cardiovascular risk prediction.

Interpretability and clinical trust

Clinicians may be reluctant to act upon recommendations from opaque algorithms. Advances in explainable AI, including feature importance plots, individual prediction explanations, and counterfactual reasoning, can help bridge this gap and make model predictions more interpretable and actionable17, 36, 37 While explainability is essential, the successful implementation of AI-based CVD risk prediction tools also depends on broader considerations, including clinician trust, local validation, usability, and alignment with clinical workflows. Validating models in the populations they are intended to serve, minimizing alert burden, and providing adequate end-user training may support more effective adoption. Co-design with clinicians and other stakeholders can further enhance usability and point-of-care actionability, helping to ensure that explainable AI tools translate into meaningful improvements in cardiovascular risk management for patients with SLE35

External validation

Most ML models for SLE-CVD prediction have been developed in single-center cohorts, raising concerns about generalizability. Rigorous external validation in diverse, independent cohorts is essential before clinical deployment36, 37 While evidence specific to SLE remains limited, broader methodological guidance in cardiovascular AI highlights the importance of evaluating model performance across different geographic regions, healthcare systems, and care settings, as well as across racial/ethnic, socioeconomic, and age subgroups. Assessing calibration, subgroup performance, fairness, clinical utility, and temporal stability can further strengthen confidence in model reliability. Multi-site collaborations and data-sharing initiatives will be critical to enabling the robust external validation needed to ensure that ML-based CVD risk prediction tools are both accurate and equitable across diverse SLE populations.

The path forward

Realizing AI’s potential for precision cardiovascular care in SLE will require sustained collaboration among rheumatologists, cardiologists, data scientists, implementation scientists, patient advocates, and health equity researchers to define how AI models can be integrated into detection and treatment pathways. Priority areas for future investigation include: (1) multi-center prospective studies validating AI prediction tools across diverse patient populations; (2) investigation of whether AI-guided risk stratification may improve clinical outcomes; (3) development of decision support tools combining AI risk predictions with evidence-based treatment recommendations; (4) incorporation of patient-reported outcomes and wearable device data into dynamic risk models; (5) ethical frameworks ensuring AI promotes rather than undermines health equity; and (6) cost-effectiveness analyses of AI-based approaches37.

Limitations

This review has several inherent limitations. As a narrative review without a pre-registered protocol, it does not meet the standards of a systematic review, and we did not apply formal PRISMA reporting. The search was restricted to English-language publications, which may introduce language bias and underrepresent findings from non-English-speaking regions. Study selection relied on reviewer judgment rather than independent dual-reviewer assessment with formal inter-rater reliability, introducing potential selection bias. The rapidly evolving AI and machine learning landscape means the review does not capture studies published after March 2026. Finally, the predominance of evidence from high-income, primarily North American settings limits direct generalizability to low- and middle-income country contexts.

Conclusions

Cardiovascular disease is one of the leading causes of mortality among individuals with SLE, driven by a complex interplay of disease-specific pathophysiology, traditional cardiovascular risk factors, and social determinants of health. This narrative review synthesizes evidence demonstrating that socioeconomic disadvantage, limited healthcare access, education inequities, and exposure to structural racism systematically elevate CVD risk in vulnerable SLE populations, particularly Black and Hispanic individuals. Lifestyle factors, including physical inactivity, tobacco use, and poor dietary patterns, further compound this vulnerability. Healthcare providers must adopt comprehensive, equity-focused approaches to CVD prevention in SLE that extend beyond traditional biomedical interventions to address social determinants, cultural factors, and structural barriers to health20, 32, 33.

Critical evidence gaps define the priorities for future research in SLE-CVD prevention. Prospective multi-center validation of SLE-specific AI risk prediction models in diverse populations is urgently needed before clinical deployment. Randomized controlled trials examining whether AI-guided, SDOH-informed interventions improve major cardiovascular outcomes in SLE have not yet been conducted. Longitudinal biomarker research is needed to understand how socioenvironmental exposures interact with SLE disease activity to amplify CVD risk. Implementation science research is needed to understand equitable deployment of AI tools in under-resourced and LMIC settings. Addressing these gaps should be a priority for future precision prevention research in SLE. Integrating lifestyle and SDOH data with clinical variables may improve risk discrimination beyond conventional risk assessment and could identify high-risk individuals who may benefit from targeted preventive interventions. However, careful attention to algorithmic bias, health equity, external validation, and ethical implementation is essential. Future research should prioritize external validation of AI tools, clinical outcome studies, and interventions that address social determinants among disadvantaged SLE populations. Only through sustained commitment to both scientific innovation and health equity can we reduce the burden of cardiovascular disease and improve quality of life for all individuals living with SLE.

Data availability

No datasets were generated or analysed during the current study.

Abbreviations

SLE:

systemic lupus erythematosus

AI:

artificial intelligence

CVD:

cardiovascular disease

References

  1. Centers for Disease Control and Prevention, Lupus & Published (2024). Available from: https://www.cdc.gov/lupus. Accessed 20 October 2025.

  2. Alammari, Y. et al. Cardiovascular morbidity in systemic lupus erythematosus: a single-center retrospective study. Cureus. 16 (4), e57842. https://doi.org/10.7759/cureus.57842 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Barbhaiya, M. et al. Race/ethnicity and cardiovascular events among patients with systemic lupus erythematosus. Arthritis Rheumatol. 69 (9), 1823–1831. https://doi.org/10.1002/art.40174 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Joyce, D. P. et al. Prevalence of cardiovascular events in a population-based registry of patients with systemic lupus erythematosus. Arthritis Res. Ther. 26 (1), 160. https://doi.org/10.1186/s13075-024-03395-6 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Bello, N., Meyers, K. J., Workman, J., Hartley, L. & McMahon, M. Cardiovascular events and risk in patients with systemic lupus erythematosus: systematic literature review and meta-analysis. Lupus. 32 (3), 325–341. https://doi.org/10.1177/09612033221147471 (2023).

    Article  CAS  PubMed  Google Scholar 

  6. Wong, C. Y. et al. Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis. Lupus Sci. Med. 11 (1), e001152. https://doi.org/10.1136/lupus-2024-001152 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sircana, M. C., Erre, G. L., Castagna, F. & Manetti, R. Crosstalk between inflammation and atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus: is there a common basis? Life (Basel). 14 (6), 716. https://doi.org/10.3390/life14060716 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Oliveira, C. B. & Kaplan, M. J. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol. 44 (3), 309–324. https://doi.org/10.1007/s00281-022-00922-y (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kostopoulou, M., Nikolopoulos, D., Parodis, I. & Bertsias, G. Cardiovascular disease in systemic lupus erythematosus: recent data on epidemiology, risk factors, and prevention. Curr. Vasc Pharmacol. 18 (6), 549–565. https://doi.org/10.2174/1570161118666191227101636 (2020).

    Article  CAS  PubMed  Google Scholar 

  10. Papazoglou, N., Kravvariti, E., Konstantonis, G., Sfikakis, P. P. & Tektonidou, M. G. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatol. (Oxford). 63 (1), 50–57. https://doi.org/10.1093/rheumatology/kead184 (2024).

    Article  CAS  Google Scholar 

  11. Lu, M. C. & Koo, M. Effects of exercise intervention on health-related quality of life in patients with systemic lupus erythematosus: a systematic review and meta-analysis of controlled trials. Healthc. (Basel). 9 (9), 1215. https://doi.org/10.3390/healthcare9091215 (2021).

    Article  Google Scholar 

  12. Lu, X. et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: systematic review and meta-analysis. Int. Immunopharmacol. 94, 107466. https://doi.org/10.1016/j.intimp.2021.107466 (2021).

    Article  CAS  PubMed  Google Scholar 

  13. Blaess, J. et al. Recommendations for physical activity and exercise in persons living with systemic lupus erythematosus: consensus by an international task force. RMD Open. 10 (2), e004171. https://doi.org/10.1136/rmdopen-2024-004171 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang, W. T. et al. Effects of tobacco smoking on cardiovascular disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Front. Immunol. 13, 967506. https://doi.org/10.3389/fimmu.2022.967506 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Garg, S. et al. Timing and predictors of incident cardiovascular disease in systemic lupus erythematosus: risk occurs early and highlights racial disparities. J. Rheumatol. 50 (1), 84–92. https://doi.org/10.3899/jrheum.220279 (2023).

    Article  PubMed  Google Scholar 

  16. Falasinnu, T., Chaichian, Y., Palaniappan, L. & Simard, J. F. Unraveling race, socioeconomic factors, and geographical context in the heterogeneity of lupus mortality in the United States. ACR Open. Rheumatol. 1 (3), 164–172. https://doi.org/10.1002/acr2.1024 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  17. Liu, C. et al. Identification of crucial genes for predicting the risk of atherosclerosis with system lupus erythematosus based on comprehensive bioinformatics analysis and machine learning. Comput. Biol. Med. 152, 106388. https://doi.org/10.1016/j.compbiomed.2022.106388 (2023).

    Article  CAS  PubMed  Google Scholar 

  18. Baethge, C., Goldbeck-Wood, S. & Mertens, S. SANRA scale for the quality assessment of narrative review articles. Res. Integr. Peer Rev. 4, 5. https://doi.org/10.1186/s41073-019-0064-8 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Pons-Estel, B. A. et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among Hispanics. Med. (Baltim). 2004; 83 (1), 1–17. https://doi.org/10.1097/01.md.0000104742.42401.e2

    Article  Google Scholar 

  20. Alarcón, G. S. et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann. Rheum. Dis. 65 (9), 1168–1174. https://doi.org/10.1136/ard.2005.040774 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  21. Raymond, W. D., Hamdorf, M., Furfaro, M., Eilertsen, G. O. & Nossent, J. C. Smoking is associated with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus. Lupus Sci. Med. 8 (1), e000537. https://doi.org/10.1136/lupus-2021-000537 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sieczkowska, S. M. et al. Effects of lifestyle intervention on cardiovascular risk factors in systemic lupus erythematosus patients: the study Living well with lupus. Clin. Rheumatol. 43 (3), 1003–1013. https://doi.org/10.1007/s10067-024-06870-2 (2024).

    Article  PubMed  Google Scholar 

  23. Duarte-García, A. & Yazdany, J. Cardiovascular disease disparities in systemic lupus erythematosus. J. Rheumatol. 50 (1), 9–10. https://doi.org/10.3899/jrheum.220933 (2023).

    Article  PubMed  Google Scholar 

  24. Maynard, J. W., Fang, H. & Petri, M. Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus. J. Rheumatol. 39 (4), 777–783. https://doi.org/10.3899/jrheum.110724 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ha Dinh, T. T., Bonner, A., Clark, R., Ramsbotham, J. & Hines, S. The effectiveness of the teach-back method on adherence and self-management in health education for people with chronic disease: a systematic review. JBI Database Syst. Rev. Implement. Rep. 14 (1), 210–247. https://doi.org/10.11124/jbisrir-2016-2296 (2016).

    Article  Google Scholar 

  26. McMahon, M., Seto, R. & Skaggs, B. J. Cardiovascular disease in systemic lupus erythematosus. Rheumatol. Immunol. Res. 2 (3), 157–172. https://doi.org/10.2478/rir-2021-0022 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Shantz, E. et al. Towards an understanding of the biopsychosocial determinants of CVD in SLE: a scoping review. Lupus Sci. Med. 11 (2), e001155. https://doi.org/10.1136/lupus-2024-001155 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sun, K. et al. Implementation of a clinician-led medication adherence intervention among patients with systemic lupus erythematosus. J. Rheumatol. 51 (9), 884–890. https://doi.org/10.3899/jrheum.2024-0071 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  29. Herndon, S. et al. A qualitative study of facilitators of medication adherence in systemic lupus erythematosus: perspectives from rheumatology providers/staff and patients. Lupus. 33 (2), 137–144. https://doi.org/10.1177/09612033231225843 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  30. Emamikia, S., Gentline, C., Enman, Y. & Parodis, I. How can we enhance adherence to medications in patients with systemic lupus erythematosus? Results from a qualitative study. J. Clin. Med. 11 (7), 1857. https://doi.org/10.3390/jcm11071857 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  31. Fava, A. & Petri, M. Systemic lupus erythematosus: diagnosis and clinical management. J. Autoimmun. 96, 1–13. https://doi.org/10.1016/j.jaut.2018.11.001 (2019).

    Article  PubMed  Google Scholar 

  32. Yazdany, J., Trupin, L., Schmajuk, G., Katz, P. & Yelin, E. Quality of care for lupus in a safety-net clinic: using chart audit to identify disparities. Arthritis Care Res. (Hoboken). 64 (6), 872–879. https://doi.org/10.1002/acr.21600 (2012).

    Article  CAS  Google Scholar 

  33. Drenkard, C. & Lim, S. S. Update on lupus epidemiology: advancing health disparities research through the study of minority populations. Curr. Opin. Rheumatol. 31 (6), 689–696. https://doi.org/10.1097/BOR.0000000000000646 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pocovi-Gerardino, G. et al. Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatol. (Oxford). 60 (1), 160–169. https://doi.org/10.1093/rheumatology/keaa210 (2021).

    Article  CAS  Google Scholar 

  35. Damen, J. A. et al. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 17 (1), 109. https://doi.org/10.1186/s12916-019-1340-7 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  36. Choi, M. Y. et al. Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus. Semin Arthritis Rheum. 67, 152468. https://doi.org/10.1016/j.semarthrit.2024.152468 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  37. Liu, S. et al. Developing an interpretable machine learning model for early prediction of cardiovascular involvement in systemic lupus erythematosus. J. Inflamm. Res. 18, 8629–8641. https://doi.org/10.2147/JIR.S526608 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ward, A. et al. Machine learning and atherosclerotic cardiovascular disease risk prediction in a multi-ethnic population. npj Digit. Med. 3, 125. https://doi.org/10.1038/s41746-020-00331-1 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kakadiaris, I. A. et al. Machine learning outperforms the ACC/AHA CVD risk calculator in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort. J. Am. Heart Assoc. 7 (22), e009476. https://doi.org/10.1161/JAHA.118.009476 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. College of Nursing and Health Sciences, Seattle University, Seattle, WA, USA

    Fatemeh Choupani

  2. School of Nursing, University of Washington, Seattle, WA, USA

    Fatemeh Choupani

  3. Biomedical Engineering Department, William A. Brookshire Department of Chemical and Biomolecular Engineering, Cullen College of Engineering, University of Houston, Houston, TX, USA

    Renita E. Horton

  4. Natural Sciences, College of Sciences and Technology, University of Houston Downtown, Houston, TX, USA

    Xyanthine Parillon

  5. Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Chan Medical School, Worcester, MA, USA

    Zaida G. Ramirez-Ortiz

  6. Department of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, USA

    Lalita Wadhwa

  7. Environmental Sciences Graduate Program, Oregon State University, Corvallis, OR, USA

    Joyonna Gamble-George

Authors

  1. Fatemeh Choupani
  2. Renita E. Horton
  3. Xyanthine Parillon
  4. Zaida G. Ramirez-Ortiz
  5. Lalita Wadhwa
  6. Joyonna Gamble-George

Contributions

FC: Conceptualization, writing original draft, writing review & editing, Supervision, REH: Writing original draft, writing review & editing. XP: Writing original draft, writing review & editing. ZGR-O: writing original draft, writing review & editing. LW: Writing review & editing. JGG: writing review & editing, Supervision. All authors read and approved the final manuscript.

Author Biographies

Fatemeh Choupani (FC) is a Tenure-Track Assistant Professor in the College of Nursing and Health Sciences at Seattle University and an Affiliate Faculty member at the University of Washington School of Nursing. She is a registered nurse with extensive clinical experience in critical care, oncology, and psychiatric–mental health nursing. Her research focuses on health equity, social determinants of health, cardiovascular risk in autoimmune diseases, particularly systemic lupus erythematosus, and the ethical integration of artificial intelligence in nursing education and precision health. https://orcid.org/0000-0002-1679-8729

Renita E. Horton (REH) serves as an Assistant Professor in Biomedical Engineering and holds an affiliated appointment with the William A. Brookshire Department of Chemical and Biomolecular Engineering at the University of Houston, Houston, TX, USA. Her work has focused on organs-on-chips, autoimmunity and lupus, and cardiovascular disease modeling. Academic profile: ORCID: https://orcid.org/0000-0001-7589-9485

Xyanthine Parillon (XP) is a researcher affiliated with Natural Sciences, College of Sciences and Technology, University of Houston Downtown, Houston, TX, USA. Her research interests include lifestyle determinants of chronic disease, behavioral health interventions, autoimmunity, AI/ML modeling, and preventive medicine in autoimmune disease populations. Academic profile: ORCID: https://orcid.org/0000-0002-4780-508X

Zaida G. Ramirez-Ortiz (ZGR-O) is a researcher and Tenure-track Assistant Professor in the Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. Her scholarly interests include clinical immunology and autoimmunity, clinical informatics, artificial intelligence in rheumatology and cardiovascular medicine, and health equity in AI model development. Academic profile: https://orcid.org/0000-0002-0253-0473

Lalita Wadhwa (LW) is a clinician-researcher affiliated with the Department of Congenital Heart Surgery, Baylor College of Medicine, Houston, TX, USA. Her expertise encompasses cardiovascular medicine and interdisciplinary cardiovascular risk management in complex patient populations. Academic profile: ORCID ID: https://orcid.org/0000-0003-4506-7826

Joyonna Gamble-George (JGG) is a researcher affiliated with the Environmental Sciences Graduate Program, Oregon State University, Corvallis, OR, USA. Her research focuses on environmental health sciences, structural determinants of health equity, translational research methodology, multi-omics, and artificial intelligence. Academic profile: https://orcid.org/0000-0002-5492-9216

Corresponding author

Correspondence to Fatemeh Choupani.

Ethics declarations

Ethics approval and consent to participate

This study did not require ethics approval. This manuscript is a narrative review synthesizing previously published peer-reviewed research; no primary data involving human participants were collected or analyzed.

Professional Relationships

All authors are research collaborators with pre-existing professional relationships established across multiple projects addressing health equity, chronic disease prevention, and clinical innovation. Fatemeh Choupani (FC) is the connecting collaborator through whose network all author relationships are established. FC and JGG also have a mentor–mentee relationship. These professional relationships do not raise any conflicts of interest

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choupani, F., Horton, R.E., Parillon, X. et al. Social determinants of health, lifestyle factors, and artificial intelligence in cardiovascular risk stratification for systemic lupus erythematosus: a narrative review. Sci. Rev. 1, 34 (2026). https://doi.org/10.1038/s44573-026-00037-7

Download citation

  • Received: 27 May 2026

  • Revised: 30 September 2026

  • Accepted: 16 October 2026

  • Published: 20 November 2026

  • Version of record: 20 November 2026

  • DOI: https://doi.org/10.1038/s44573-026-00037-7

Keywords

来源:Nature 健康护理主题 · nature.com